清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

COPD—more than just tobacco smoke

医学 慢性阻塞性肺病 慢性支气管炎 肺活量测定 罗氟司特 重症监护医学 戒烟 支气管炎 肺病 疾病 内科学 哮喘 病理
作者
The Lancet
标识
DOI:10.1016/s0140-6736(09)61535-x
摘要

On Sept 12–16, Vienna hosts the European Respiratory Society's annual congress, the largest in pulmonary medicine in the world. As a prelude to the meeting, The Lancet today is devoted to chronic obstructive pulmonary disease (COPD). WHO estimates that 210 million people have COPD worldwide. This number could be higher because many people with COPD often do not seek medical help until the disease worsens. COPD is now an umbrella term to cover emphysema and chronic bronchitis, among others, all of which used to be considered separate conditions. The disease is the fourth leading cause of death in the world, but by 2030 it is expected to be the third, behind ischaemic heart disease and cerebrovascular disease. With such a high burden, emphasis on better diagnosis, management, and identification of at-risk groups must be achieved. In today's issue, Joan Soriano and colleagues review spirometry, the mainstay of diagnosis. They call for better screening with spirometry, because early detection correlates with better outcomes. Spirometry is also used to classify COPD into four subgroups—mild, moderate, severe, and very severe. This classification helps guide the type of treatment options offered. For most patients, longacting inhaled β2 agonists, inhaled antimuscarinics, and inhaled corticosteroids in differing combinations are the foundation of effective management. Treatment with the anti-inflammatory phosphodiesterase-4 inhibitor roflumilast is presented in two randomised trials from Peter Calverley's group. The overall findings of the two studies suggest that there is benefit to patients with COPD, with a reduction in exacerbations, and improvement in lung function, when roflumilast is combined with a longacting bronchodilator or longacting inhaled antimuscarinics. For a long time COPD has been thought of as a smokers' disease, and not without reason. Those who smoke damage their lungs and create the pathophysiological environment for this disease. However, as Holger Schünemann points out in a Comment in today's issue, a worldwide ban on tobacco would indeed benefit health substantially both at the population and individual level—yet the world is not ready for such a bold ban. Sundeep Salvi and Barnes explore the aetiology of COPD and highlight the need for greater focus on risk factors other than smoking. They argue that smoking is not the biggest risk factor for COPD, and that this has been reported as early as 1963. Interest in COPD in non-smokers has increased in the past 5 years, although smoking has still remained the emphasis of most research. The Global initiative for chronic Obstructive Lung Disease (GOLD) points out in its guidelines that COPD is caused by “Tobacco smoke, occupational dusts and chemicals, indoor air pollution and outdoor air pollution”, putting these inhalation exposures under one blanket. Salvi and Barnes take this further, listing indoor air pollution from biomass fuel, pulmonary tuberculosis, chronic asthma, and socioeconomic status as additional risk factors in the development of COPD. Previous evidence suggests that occupational exposure to different compounds can lead to long-term severe sequelae in the respiratory system (eg, asbestos and mesothelioma); therefore, it is not a great leap to think that occupational exposures are also important risk factors for COPD. In parts of Africa tuberculosis is synonymous with HIV and therefore a diagnosis of either carries a large stigma. If patients with tuberculosis have an increased risk of COPD, could this population be under-represented in this continent? Will patients who have symptoms not present to health-care providers for fear of a diagnosis of tuberculosis, when in fact it is COPD? Education and increased awareness could be an answer for some of these patients, as well as an increased effort to destigmatise the association of tuberculosis and HIV by those health-care professionals working within this community. Chronic asthma is also of interest because it carries a greater risk of developing COPD than that caused by smoking. If asthma development is on the increase around the world, COPD incidence is likely to increase as well, perhaps even more so than the current predictions. Biomass fuel (coal, wood, and charcoal) has an exposed population of 3 billion, compared with 1 billion for those exposed to tobacco—making such fuel an important target in COPD prevention. This problem is not just one for developing countries. Even if over half of those who have COPD are non-smokers, the battle against smoking and health promotion to quit smoking should continue. However, the identification and education of those who are at risk from other inhalation exposures, both at home and at work, especially in developing countries, also needs to become a priority. From BODE to ADO to outcomes in multimorbid COPD patientsThe resources spent on research and treatment into chronic obstructive pulmonary disease (COPD) seem ludicrous compared with what could be achieved by simple and better legislation. In fact, the world needs to ban tobacco. Unfortunately, partly because many policy makers have failed to act appropriately, reality is different. COPD remains a major public health concern and is high on the priority list of major organisations, such as WHO.1 Full-Text PDF Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsSince different subsets of patients exist within the broad spectrum of COPD, targeted specific therapies could improve disease management. This possibility should be explored further in prospective studies. Full-Text PDF Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsRoflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients. Full-Text PDF Screening for and early detection of chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease (COPD) is a substantially underdiagnosed disorder, with the diagnosis typically missed or delayed until the condition is advanced. Spirometry is the most frequently used pulmonary function test and enables health professionals to make an objective measurement of airflow obstruction and assess the degree to which it is reversible. As a diagnostic test for COPD, spirometry is a reliable, simple, non-invasive, safe, and non-expensive procedure. Early diagnosis of COPD should provide support for smoking cessation initiatives and lead to reduction of the societal burden of the disease, but definitive confirmation of both proves elusive. Full-Text PDF Chronic obstructive pulmonary disease in non-smokersChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Tobacco smoking is established as a major risk factor, but emerging evidence suggests that other risk factors are important, especially in developing countries. An estimated 25–45% of patients with COPD have never smoked; the burden of non-smoking COPD is therefore much higher than previously believed. About 3 billion people, half the worldwide population, are exposed to smoke from biomass fuel compared with 1·01 billion people who smoke tobacco, which suggests that exposure to biomass smoke might be the biggest risk factor for COPD globally. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
17秒前
香蕉觅云应助科研通管家采纳,获得10
22秒前
Owen应助科研通管家采纳,获得10
22秒前
海藏进星辰完成签到,获得积分10
36秒前
卷卷完成签到,获得积分10
40秒前
43秒前
ktw完成签到,获得积分10
44秒前
kmzzy完成签到,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
3分钟前
3分钟前
一条摆摆的沙丁鱼完成签到 ,获得积分10
4分钟前
4分钟前
yyf发布了新的文献求助10
4分钟前
claud完成签到 ,获得积分0
4分钟前
yyf完成签到,获得积分10
4分钟前
ffdhdh完成签到,获得积分10
4分钟前
白天科室黑奴and晚上实验室牛马完成签到 ,获得积分10
6分钟前
6分钟前
Akim应助亦风采纳,获得10
6分钟前
6分钟前
亦风发布了新的文献求助10
6分钟前
情怀应助刘紫媛采纳,获得10
6分钟前
科研通AI2S应助亦风采纳,获得10
6分钟前
亦风完成签到,获得积分10
6分钟前
7分钟前
偷得浮生半日闲完成签到 ,获得积分10
7分钟前
jintian完成签到 ,获得积分10
7分钟前
7分钟前
fufufu123完成签到 ,获得积分10
8分钟前
桐桐应助科研通管家采纳,获得10
8分钟前
puzhongjiMiQ完成签到,获得积分10
8分钟前
9分钟前
李健的粉丝团团长应助lzzz采纳,获得10
9分钟前
9分钟前
刘紫媛发布了新的文献求助10
10分钟前
Raul完成签到 ,获得积分10
10分钟前
lql完成签到 ,获得积分10
10分钟前
可爱的函函应助鲅鱼圈采纳,获得10
11分钟前
11分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990469
求助须知:如何正确求助?哪些是违规求助? 3532166
关于积分的说明 11256513
捐赠科研通 3271046
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234